Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment.

ABSTRACT:

Purpose

Lutetium-177-Dotatate (Lutathera^®) is a combined radionuclide-peptide that is FDA-approved for the treatment of well-differentiated, somatostatin receptor-positive, gastroenteropancreatic neuroendocrine tumors. Carcinoid crisis is a rare, but potentially life-threatening risk of this radiopharmaceutical, of which prompt recognition and treatment is essential to reducing morbidity. This manuscript provides an overview of the topic to promote awareness of this adverse event, with emphasis on early recognition and management. In addition, we present our institution's experience with Lutetium-177-Dotatate-associated complications across a five-year period.

Methods

A literature review of lutetium-177-dotatate therapy and its potential implication of carcinoid c

SUBMITTER: Sozio SJ 

PROVIDER: S-EPMC11393224 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature